Bao is Erasca’s Vice President of Regulatory Affairs, bringing 15 years of regulatory experience in oncology product development, ranging from pre-IND through registration phase. Prior to Erasca, Bao was head of regulatory affairs at IDEAYA Biosciences. Before that, she was head of regulatory affairs at Ignyta, where she helped drive the development plan for Rozlytrek® from Phase 1 to registration-enabling Phase 2, supporting both tissue-specific and tissue-agnostic indications. She was previously head of regulatory affairs at Seragon Pharmaceuticals and Aragon Pharmaceuticals, where she helped advance the development of Erleada®, the first FDA-approved therapy for non-metastatic castration-resistant prostate cancer using a novel clinical endpoint. She also held regulatory lead positions of increasing responsibility at Genentech for multiple oncology products, including Erivedge®, the first FDA-approved therapy for advanced basal cell carcinoma, Kadcyla®, Gazyva®, Tarceva® and Herceptin®. Earlier in her career, Bao worked in oncology research at the University of California, San Diego and the University of California, San Francisco.
She earned her B.S. in biochemistry from the University of California, San Diego.